Clinical Trial Update: NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study of NB02 (POSELTINIB) as monotherapy for relapsed/refractory non-Hodgkin lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• POSELTINIB (POSELTINIB)

Snippet

Sponsor: NOBO Medicine | Conditions: Non Hodgkin Lymphoma (NHL) | Phase 1 | Status: RECRUITING